We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Biochemistry
-
1. De novo designed proteins: a breakthrough in snakebite treatment
- Dr. Susana Vazquez Torres
- Cancer/Oncology
-
2. Neoantigen vaccines in cancer immunotherapy: a breakthrough in renal cell carcinoma- Dr. David A. Braun
-
4. From lab to clinic: bridging cancer genetics and public health
- Prof. Clare Turnbull
-
5. Engineered yeast: a breakthrough in targeted cancer therapies
- Prof. Gautam Dantas
-
7. Cancer vaccines
- Dr. Elias Sayour
-
8. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
10. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
11. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Immunology & Inflammation
-
12. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
13. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
15. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
17. Kalihinol analog MED6-189: a promising pan-antimalarial candidate
- Prof. Karine Le Roch
-
18. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
20. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Methods
-
22. How big data and genomics are personalizing your health
- Prof. Michael Snyder
-
23. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
24. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
25. MassBank development and future
- Dr. Emma L. Schymanski
-
26. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
27. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
- Neurology/Neuroscience
-
29. Rethinking the amyloid dogma in Alzheimer’s disease
- Prof. George Perry
-
30. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
31. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
32. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
33. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
34. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
35. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
36. Muscarinic acetylcholine receptor modulation in neurological diseases
- Prof. Andrew B. Tobin
- Pharmaceutical Sciences
-
37. Unlocking a cryptic pocket: a new approach to safer pain relief- Prof. Susruta Majumdar
- Dr. Vipin Ashok Rangari
-
38. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
39. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
41. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
42. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
43. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
44. The regulation of cell therapy
- Prof. Moutih Rafei
-
45. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
46. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
48. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
49. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
Topics Covered
- Duchenne muscular dystrophy (DMD) pathology
- Dystrophin structure and function
- DMD genetics
- Muscle degeneration
- Fibrosis progression
- Cardiomyopathy in DMD
- Exon skipping therapy
- Genetic diagnosis
- Early intervention
Biography
Prof. Steve Wilton is the Foundation Professor of Molecular Therapy at Murdoch University and Director of the Perron Institute for Neurological and Translational Science in Australia. He is internationally recognised for pioneering antisense oligonucleotide therapies for Duchenne muscular dystrophy (DMD), work that led to the development of the first FDA-approved dystrophin-restoring treatments for DMD. His research focuses on precision genetic therapies for neuromuscular and neurological disorders, and he has received numerous honours for his contributions to translational medical research, including appointment as an Officer of the Order of Australia (AO).
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wilton, S. (2026, June 30). Duchenne muscular dystrophy: pathology, diagnostic strategies, and core molecular pathways [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 2, 2026, from https://doi.org/10.69645/PYCT6740.Export Citation (RIS)
Publication History
- Published on June 30, 2026
Financial Disclosures
- Prof. Steve Wilton has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Duchenne muscular dystrophy: pathology, diagnostic strategies, and core molecular pathways
Published on June 30, 2026
14 min
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Prof.
Steve Wilton is
a leading molecular geneticist
and a pioneer of
antisense therapy
whose work has been central to
developing treatments for
Duchenne muscular dystrophy.
Today, he joins us to discuss
the disease's pathology,
the underlying
molecular pathways,
and key diagnosis strategies.
Prof. Wilton, thank you so
much for joining us today.
Prof. Wilton:
Absolute pleasure.
Interviewer: So let's start
with the molecular basis
of Duchenne muscular dystrophy.
Can you take us through
what is the molecular basis
and what is the role of
dystrophin in healthy muscles?
Prof. Wilton: Duchenne
muscular dystrophy is caused by
spelling errors or mutations in
the massive dystrophin gene.
These errors compromise
the gene message.
They stop the instructions
from being able to make
a full-length
functional protein.
The dystrophin gene is the
largest one in the human genome,
spanning almost
2.3 million bases.
The average gene is 30000 bases
long, and has 8-10 exons.
This is 2.3 million
bases and has 79 exons
for the full-length
muscle isoform,
which, when it's
correctly processed,
generates a mature messenger
RNA of about 14000 bases.
This is then translated
into a protein.
A protein that's 3685
amino acids long.
Think of this large protein
as a molecular shock
absorber for the muscle.
Both ends are needed
for function.
The problem with
the dystrophin gene
is that there are fragile
sites within the gene
that make it highly susceptible
to breaks and rearrangements.
Hence, almost two-thirds of
Duchenne-causing mutations
are deletions of
one or more exons